- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04037072
Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures
April 1, 2022 updated by: Fox Chase Cancer Center
GI-108: Randomized Controlled Double-Blinded Trial Assessing the Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures
This study evaluates Mitomycin C as treatment for dysphagia in adult subjects with documented complex esophageal anastomotic strictures.
Patients will be randomized in a double-blinded fashion to topical application of normal saline (NS) or Mitomycin C (MMC) at the time of time of index procedure.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent and HIPAA consent document
- Patients must have symptomatic (dysphagia ≥2), treatment naïve complex esophageal anastomotic stricture (length >2 cm or diameter ≤9mm).
- Age ≥ 18
- Esophago-gastro or esophago-jejunal anastomosis with or without having undergone neoadjuvant or adjuvant radio-chemotherapy
- Any patient taking antiplatelet agents such as Plavix, Effient, Brilinta, Aggrenox must be able to hold the drugs 5 days prior to dilation and may resume 3 days after the dilation.
- Any patient on vitamin K antagonists such as warfarin must be able to hold the drugs 5 days prior to dilation and may resume 3 days after the dilation. INR should be checked for such patients at least 24 hours before dilation and it must be < 1.5
- Patients taking direct thrombin inhibitors such as Pradaxa, Angiomax must be able to hold the drugs 5 days prior to dilation and may resume 3 days after the dilation
- Patients taking Factor Xa inhibitors must be able to hold the drugs 2 days prior to dilation and may resume 3 days after dilation
- Patients taking GIIB/IIIA inhibitors must be able to hold the drugs1 day prior to dilation and resume 3 days after the dilation.
- Patients taking unfractionated heparin must be able to hold the drug 6 hours before dilation and low molecular weight heparin must be held 24 hours before dilation. Unfractionated heparin may resume immediately after the dilation while low molecular weight heparin may resume 3 days after dilation
Exclusion Criteria:
- Patients with malignant strictures
- Patients with non-complex benign strictures.
- Patients with anastomosis creation within ≤ 2 weeks
- Patients with suspected gastrointestinal perforation or leak that could result in extraluminal extravasation of Mitomycin C
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or breast feeding. Refer to section 4.4 for further detail.
- Patients receiving systemic chemotherapy during the treatment of esophageal stricture.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mitomycin C
Cotton swab or strip of 2x2 cotton gauze soaked with 0.4mg/mL Mitomycin C
|
Topical application of Mytomycin C (MMC)
Other Names:
|
Placebo Comparator: Control
Cotton swab or strip of 2x2 cotton gauze soaked with Normal saline
|
Topical application of Normal Saline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of dysphagia ≥ grade 1 after the dilation procedure
Time Frame: 6 months
|
Prevalence of dysphagia grade ≥1 in MMC Vs normal saline treated patients until 6 months after the first follow-up.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of procedures needed to reach dilation goal
Time Frame: 30 days
|
calculated from the first treatment procedure until the last one and will be compared between the experimental and the control arm.
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 3, 2020
Primary Completion (Anticipated)
March 15, 2022
Study Completion (Anticipated)
December 15, 2022
Study Registration Dates
First Submitted
July 25, 2019
First Submitted That Met QC Criteria
July 25, 2019
First Posted (Actual)
July 30, 2019
Study Record Updates
Last Update Posted (Actual)
April 11, 2022
Last Update Submitted That Met QC Criteria
April 1, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Pathological Conditions, Anatomical
- Esophageal Diseases
- Constriction, Pathologic
- Esophageal Stenosis
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Alkylating Agents
- Antibiotics, Antineoplastic
- Mitomycins
- Mitomycin
Other Study ID Numbers
- 18-1022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Stenosis
-
Peking University Third HospitalCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingEsophageal Stenosis | Caustic Esophageal Injury | Pharyngeal Stenosis
-
E-DA HospitalRecruitingEsophageal Neoplasms | Esophagus StenosisTaiwan
-
Kansas City Veteran Affairs Medical CenterCompletedGastrostomy | Head and Neck Neoplasm | Esophageal Stenosis and ObstructionUnited States
-
Istituto Clinico HumanitasRecruiting
-
NYU Langone HealthWithdrawn
-
Radboud University Medical CenterUMC Utrecht; Erasmus Medical Center; The Netherlands Cancer Institute; Leiden University...RecruitingEsophageal Stricture | Anastomotic Stenosis | Dilation of Esophagus Due to DiseaseNetherlands
-
AdventHealthTerminated
-
Radboud University Medical CenterUnknownBenign Esophageal StrictureNetherlands
-
Nagasaki UniversityUnknownEsophageal Anastomotic StrictureJapan
Clinical Trials on Mitomycin C
-
Guy's and St Thomas' NHS Foundation TrustUnknownPrimary Open Angle GlaucomaUnited Kingdom
-
University of California, San DiegoCompletedOpen Angle Glaucoma
-
Medical Enterprises Ltd.TerminatedUrinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedSolid NeoplasmUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Van Andel Research InstituteWithdrawnPancreatic CancerUnited States
-
Indiana UniversityOptonolTerminated
-
Jørgen Bjerggaard JensenActive, not recruiting
-
Croatian Cooperative Group for Clinical Research...Roche Pharma AGUnknownBreast Cancer | MetastasisCroatia
-
Prakash PandalaiRecruiting
-
University of Rome Tor VergataUniversity Of Perugia; University of L'AquilaCompletedBladder Cancer TNM Staging Primary Tumor (T) Ta | Bladder Cancer TNM Staging Primary Tumor (T) T1 | Bladder Cancer Transitional Cell GradeItaly